Charles S. Adcock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles S. Adcock has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Akash Patel
Interventional Radiology, University of Mississippi Medical Center, Jackson, USA
1 shared publication - Ali Fatemi
Radiation Oncology, University of Mississippi Medical Center, Jackson, USA
1 shared publication - Candace Howard-Claudio
Department of Radiology, University of Mississippi Medical Center, Jackson, MS 39216, USA
1 shared publication - Edward Florez
Radiology, University of Mississippi Medical Center, Jackson, USA
1 shared publication - Garth Seamus Campbell
Radiology, University of Mississippi Medical Center, Jackson, USA
1 shared publication - Kevin A Zand
Radiology, University of Mississippi Medical Center, Jackson, USA
1 shared publication
Latest Publications
- Open Access
- 16 February 2019
- Published by Springer Nature in Cureus
- Vol. 11 (2) , e4083
Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab
Trans-arterial radioembolization (TARE) with Y-90 microspheres is an endovascular, liver-directed therapy suitable for treatment of locally advanced hepatocellular carcinoma (HCC) often as a way to reduce tumor size and bridge patients to resection or liver transplant. Opdivo®, or nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is an immunotherapeutic drug approved in September 2017 for the treatment of HCC in patients who have received prior sorafenib. We report on a patient with hepatocellular carcinoma with right and left portal vein involvement, bony metastasis, and possible lung metastasis. The patient showed a significant response following consecutive treatment with TARE, sorafenib, and nivolumab. Our case suggests that TARE, sorafenib, and nivolumab may have a synergistic effect on the immune response to HCC.
- 16 February 2019
- Published by Springer Nature in Cureus
- Vol. 11 (2) , e4083
Open AccessFavorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab
Trans-arterial radioembolization (TARE) with Y-90 microspheres is an endovascular, liver-directed therapy suitable for treatment of locally advanced hepatocellular carcinoma (HCC) often as a way to reduce tumor size and bridge patients to resection or liver transplant. Opdivo®, or nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is an immunotherapeutic drug approved in September 2017 for the treatment of HCC in patients who have received prior sorafenib. We report on a patient with hepatocellular carcinoma with right and left portal vein involvement, bony metastasis, and possible lung metastasis. The patient showed a significant response following consecutive treatment with TARE, sorafenib, and nivolumab. Our case suggests that TARE, sorafenib, and nivolumab may have a synergistic effect on the immune response to HCC.
- Open Access
- 29 June 2018
- Published by Springer Nature in Cureus
- Vol. 10 (6) , e2895
Assessment of Treatment Response Following Yttrium-90 Transarterial Radioembolization of Liver Malignancies
Transarterial radioembolization using yttrium-90 microspheres is an established and effective treatment for liver malignancies. Determining response to this treatment is difficult due to the radical changes that occur in tissue as a response to radiation. Though accurate assessment of treatment response is paramount for proper patient disposition, there is currently no standardized assessment protocol. Current methods of assessment often consider changes in size, necrosis, vascularity, fluorodeoxyglucose-positron emission tomography FDG-PET metabolic activity, and diffusion using diffusion-weighted magnetic resonance imaging (DWI). Current methods of assessment require a lag time of one to two months post-treatment to determine treatment effectiveness. This delay is a hindrance to obtaining better patient outcomes, giving rise to a need to identify markers for faster determination of treatment efficacy.
- 29 June 2018
- Published by Springer Nature in Cureus
- Vol. 10 (6) , e2895
Open AccessAssessment of Treatment Response Following Yttrium-90 Transarterial Radioembolization of Liver Malignancies
Transarterial radioembolization using yttrium-90 microspheres is an established and effective treatment for liver malignancies. Determining response to this treatment is difficult due to the radical changes that occur in tissue as a response to radiation. Though accurate assessment of treatment response is paramount for proper patient disposition, there is currently no standardized assessment protocol. Current methods of assessment often consider changes in size, necrosis, vascularity, fluorodeoxyglucose-positron emission tomography FDG-PET metabolic activity, and diffusion using diffusion-weighted magnetic resonance imaging (DWI). Current methods of assessment require a lag time of one to two months post-treatment to determine treatment effectiveness. This delay is a hindrance to obtaining better patient outcomes, giving rise to a need to identify markers for faster determination of treatment efficacy.